Current situation of human immunodeficiency virus type 2 and Human T lymphotropic virus in Spain;Situación actual de la infección por el virus de la inmunodeficiencia humana tipo 2 y el Virus linfotrópico de células T humano en España

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 7, 2010, Pages 442-445

  Treviño, Ana ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Epidemiology; HTLV; Human immunodeficiency virus type 1; Human immunodeficiency virus type 2; Spain

Indexed keywords

ANTIRETROVIRUS AGENT; RALTEGRAVIR;

AFRICA SOUTH OF THE SAHARA; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL ARTICLE; ENDEMIC DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMIGRATION; INTRAVENOUS DRUG ABUSE; LEUKEMIA; MALE; REVIEW; SCREENING TEST; SEX RATIO; SOUTH AND CENTRAL AMERICA; SPAIN; SPASTIC PARAPLEGIA;

EID: 77956343661     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.04.001     Document Type: Article

References (20)

1. A. Treviño, A. Aguilera, E. Caballero, C. Toro, J.M. Eiros, and R. Ortiz de Lejarazu Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain AIDS Res Hum Retroviruses 25 2009 551 554
2. Treviño A, Garca J, de Mendoza C, Benito R, Aguilera A, Ortz de Lejarazu R, et al. Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey. AIDS Res Human Retroviruses (en prensa) 2010.
3. R. Edlich, J. Arnette, and F. Williams Global epidemic of human T-cell lymphotropic virus type I (HTLV-I) J Emerg Med 18 2000 109 119
4. K. Verdonck, E. Gonzlez, S. Van Dooren, A.M. Vandamme, G. Vanham, and E. Gotuzzo Human T-lymphotropic virus 1: Recent knowledge about an ancient infection Lancet Infect Dis 7 2007 266 281
5. C. De Castro-Costa, A. Arajo, M. Barreto, O. Takayanagui, M. Sohler, and E. Da Silva Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM) AIDS Res Hum Retroviruses 22 2006 931 935
6. K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. Ramos, and W. Harrington Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting J Clin Oncol 27 2009 453 459
7. M. Silva, R. Harab, A. Leite, D. Schor, A. Arajo, and M. Andrada-Serpa Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection Clin Infect Dis 44 2007 689 692
8. S. Laperche, B. Worms, J. Pillonel European Network of Transfusion Medecine Societies; Steering Committee Blood safety strategies for human T-cell lymphotropic virus in Europe Vox Sang 96 2009 104 110
9. P. Bagossi, P. Bander, B. Bozki, and J. Tzsr Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4 Exp Rev Anti Infect Ther 7 2009 1235 1249
10. R. Mahieux, and A. Gessain The human HTLV-3 and HTLV-4 retroviruses: New members of the HTLV family Pathol Biol (Paris) 57 2009 161 166
11. W. Switzer, M. Salemi, S. Qari, H. Jia, R. Gray, and A. Katzourakis Ancient, independent evolution and distinct molecular features of the novel HTLV-4 Retrovirology 6 2009 9 29
12. B. Roquebert, F. Damond, G. Collin, S. Matheron, G. Peytavin, and A. Bnard HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro J Antimicrob Chemother 62 2008 914 920
13. F. Damond, S. Lariven, B. Roquebert, S. Males, G. Peytavin, and G. Morau Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients AIDS 22 2008 665 666
14. N. Garrett, L. Xu, E. Smit, B. Ferns, S. El-Gadi, and J. Anderson Raltegravir treatment response in an HIV-2 infected patient: A case report AIDS 31 2008 1091 1092
15. M. Salgado, C. Toro, A. Simn, C. Garrido, F. Blanco, and V. Soriano Mutation N155 H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity J Clin Virol 46 2009 173 175
16. B. Roquebert, L. Blum, G. Collin, F. Damond, G. Peytavin, J. Leleu ANRS HIV-2 Cohort Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen AIDS 22 2008 2045 2046
17. Bnard A, Van Sighem A, Taeb A, Valadas E, Ruelle J, Soriano V, et al. Immuno-virological response to triple NRTI and boosted PI in treatment-nave HIV-2-infected patients. The ACHIeV2E Collaboration Study Group. Proceedings of the 12th European AIDS Conference/EACS; 2009 Nov; Colonia, Alemania. Nov 2009 Cologne, Germany. (Abstract PS10/5)
18. N. Parkin, and J. Schapiro Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV Antivir Ther 9 2004 3 12
19. M. Witvrouw, C. Pannecouque, W. Switzer, T. Folks, E. De Clercq, and W. Heneine Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and post-exposure prophylaxis Antivir Ther 9 2004 57 65
20. B. Rods, J. Sheldon, C. Toro, V. Jimnez, M.A. Alvarez, and V. Soriano Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy J Antimicrob Chemother 57 2006 709 713